Susan Hadley, MD
Family Medicine · Tucson, AZNPI 1437148533
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,750 of the $4,396 with a category attached, or 85.3%. Merck accounts for 85.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $2,665 and has fallen 94.8% since, to $140 in 2025. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 13 payments — averaging $338.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- MDD US Operations, LLC$127
- Indivior Inc.$125
- Braeburn Inc.$122
- Pacira Therapeutics, Inc.$122
- AbbVie$94
- plus $56 from 3 others
What the payments were for
- Speaking & faculty fees$3,75085%
- Food & beverage$64615%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $3,750 |
| MDD US Operations, LLC | 2 | $127 |
| Indivior Inc. | 1 | $125 |
| Braeburn Inc. | 1 | $122 |
| Pacira Therapeutics, Inc. | 1 | $122 |
| AbbVie | 1 | $94 |
| Johnson & Johnson | 2 | $29 |
| Boston Scientific | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$3,750
- Lucemyra/Lofexidine$125
- SUBLOCADE$125
- BRIXADI$122
- Zilretta$122
How this compares
$4,396 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $56,571 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $13,289 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $3,696 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 67 | $2,051 |
| Gabapentin | 81 | $2,031 |
| Methadone Hcl | 40 | $1,526 |
| Famotidine | 39 | $1,186 |
| Oxycodone Hcl | 51 | $1,055 |
| Omeprazole | 26 | $1,016 |
| Tizanidine Hcl | 26 | $954 |
| Duloxetine Hcl | 22 | $698 |
| Ondansetron OdtOndansetron | 13 | $660 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $650 |
| Azelastine Hcl | 23 | $482 |
| Fluticasone Propionate | 14 | $430 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Tucson
- Katherine WilsonTucson$29K
- Kimy CharaniTucson$21K
- Mark GrantTucson$21K
- Christian MoherTucson$13K
- Dean WrightTucson$12K
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.